These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 27587628)

  • 1. Transdisciplinary Approach to Managing Hepatitis C Virus Infection in Patients at a Tertiary Care Cancer Center.
    Torres HA; Roach LR; Mahale P; Economides MP; Blechacz B; Miller E; Borchardt R; Rashid A; Oo TH; Shukla B; Farida M; Ericsson CD; Granwehr BP; Raad II
    J Natl Compr Canc Netw; 2016 Sep; 14(9):1185-8. PubMed ID: 27587628
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatitis C virus infection in Taiwan: Past, present, and future.
    Kao JH
    J Formos Med Assoc; 2016 Feb; 115(2):65-6. PubMed ID: 26228687
    [No Abstract]   [Full Text] [Related]  

  • 3. Introduction to hepatitis C virus (HCV) therapies special thematic issue.
    Meanwell NA; Watkins WJ
    J Med Chem; 2014 Mar; 57(5):1625-6. PubMed ID: 24484173
    [No Abstract]   [Full Text] [Related]  

  • 4. Treating hepatitis B virus/hepatitis C virus coinfected patients with direct-acting hepatitis C virus antivirals only is not safe.
    Ozaras R; Sunbul M; Parlak M; Bodur H; Leblebicioglu H
    Hepatology; 2016 Nov; 64(5):1825-1827. PubMed ID: 27043022
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatitis C virus (HCV) therapies special thematic issue: call for papers.
    Georg GI; Wang S
    J Med Chem; 2013 Jan; 56(2):387. PubMed ID: 23294104
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibition of hepatitis C entry: too soon to dismiss while many are still being denied treatment.
    Uprichard SL; Sainz B
    Gut; 2015 Apr; 64(4):690-1. PubMed ID: 25287483
    [No Abstract]   [Full Text] [Related]  

  • 7. Practical consequences of hepatitis C virus quasispecies for target-specific antivirals.
    Fanning LJ
    J Infect Dis; 2008 Sep; 198(6):797-9. PubMed ID: 18637751
    [No Abstract]   [Full Text] [Related]  

  • 8. [Issues in need for a solution among patients with successful eradication of hepatitis C virus].
    Kurosaki M; Izumi N
    Nihon Shokakibyo Gakkai Zasshi; 2016; 113(1):29-35. PubMed ID: 26743551
    [No Abstract]   [Full Text] [Related]  

  • 9. Accurate hepatitis C virus genotyping and selection of optimal therapy: lessons from a St Petersburg strain infection.
    Knops E; Heger E; Koenig C; Moebius U; Lübke N; Kaiser R; Di Cristanziano V; Hüsgen L; Kocyigit C; Rupp J; Sierra S
    Clin Microbiol Infect; 2018 Apr; 24(4):440-441. PubMed ID: 29104172
    [No Abstract]   [Full Text] [Related]  

  • 10. Viral entry inhibition: too late for hepatitis C, but promising for other viral infections.
    Pawlotsky JM
    Gut; 2015 Mar; 64(3):362-4. PubMed ID: 25098973
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of Direct-Acting Antivirals Compared with Older Agents for Hepatitis C.
    Ta K; Zehtabchi S
    Am Fam Physician; 2017 Jun; 95(11):Online. PubMed ID: 28671433
    [No Abstract]   [Full Text] [Related]  

  • 12. Bayesian network meta-analysis to evaluate interferon-free treatments in naive patients with genotype 1 hepatitis C virus infection.
    Trippoli S; Fadda V; Maratea D; Messori A
    Eur J Gastroenterol Hepatol; 2015 Aug; 27(8):983-4. PubMed ID: 26114910
    [No Abstract]   [Full Text] [Related]  

  • 13. [Expert advices for evaluating clinical trials of direct-acting antiviral agents for hepatitis C].
    Research Group for New Drug's Clinical Evalutaion of Critical Diseases and Platform Construction of Integrated Technology
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):161-4. PubMed ID: 27095756
    [No Abstract]   [Full Text] [Related]  

  • 14. [Host cholesterol biosynthesis as a potential target for anti-hepatitis C virus strategies].
    Saito K; Fukasawa M
    Seikagaku; 2016 Jun; 88(3):411-5. PubMed ID: 27483962
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment choice of the antiviral agent for the hepatitis C].
    Karino Y
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():269-73. PubMed ID: 26845943
    [No Abstract]   [Full Text] [Related]  

  • 16. [Predictive factors of response to Direct Acting Antivirals therapy Drug resistance hepatitis C virus].
    Suda G; Yamasaki K; Sakamoto N
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():189-92. PubMed ID: 26845928
    [No Abstract]   [Full Text] [Related]  

  • 17. Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials.
    Harrington PR; Deming DJ; Komatsu TE; Naeger LK
    Clin Infect Dis; 2015 Aug; 61(4):666-7. PubMed ID: 26002846
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effectiveness and safety of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection].
    Yang J; Rao HY
    Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):175-178. PubMed ID: 29804389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The interferon sensitivity determining region: all hepatitis C virus isolates are not the same.
    Herion D; Hoofnagle JH
    Hepatology; 1997 Mar; 25(3):769-71. PubMed ID: 9049233
    [No Abstract]   [Full Text] [Related]  

  • 20. Optimal duration of pre-liver transplantation anti-hepatitis C virus treatment with direct-acting agent sofosbuvir.
    Borentain P; Colson P; Darque A; Gérolami R
    Liver Int; 2015 Jun; 35(6):1776. PubMed ID: 25619265
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.